Infectious toxicity using alemtuzumab

Haematologica

Volumn 89, Issue 12, 2004, Pages 1415-1419

  Nosari, Annamaria ^a   Montillo, Marco ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; COTRIMOXAZOLE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; RITUXIMAB; THYMOCYTE ANTIBODY; VALACICLOVIR; 2 AMINOPURINE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD52 ANTIGEN; DRUG DERIVATIVE; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; OPPORTUNISTIC INFECTION; STEM CELL TRANSPLANTATION; VIRUS INFECTION; VIRUS REACTIVATION; ANTIBIOTIC PROPHYLAXIS; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE PREDISPOSITION; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; PNEUMOCYSTIS PNEUMONIA; VIREMIA; VIRUS ACTIVATION;

2-AMINOPURINE; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; CYTOMEGALOVIRUS INFECTIONS; DISEASE SUSCEPTIBILITY; GANCICLOVIR; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LYMPHOPROLIFERATIVE DISORDERS; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; TRANSPLANTATION CONDITIONING; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VIREMIA; VIRUS ACTIVATION;

EID: 10444276466     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Gilleece MH, Dexter TM. Effect of campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-12.
2. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91.
3. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, et al. Campath-1H and fludarabine combination are highly active in refractory chronic lymphocytic leukaemia. Blood 2002;99:2245-7
4. Osterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. The European Study Group of campath-1H treatment in CLL. J Clin Oncol 1997;15:1567-74.
5. Keating MJ, Flinn I, Vinay J, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
6. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukaemia who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
7. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
8. Anaissie EJ, Kontoiyannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Int Med 1998;129:559-60.
9. Byrd JC, Houde-McGrail LL, Hospental DR, Howard RS, Dow NA, Dihel LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol 1999;105:445-7.
10. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. CMV viremia during campath-1H therapy for relapsed/refractory CLL and PLL. Clin Lymph 2002;3:105-10.
11. Rai KR, Keating MJ, Coutre S, Rizzieri DA. Patients with refractory S-CLL and T-PLL on a compassionate basis. A report on efficacy and safety of CAM 511 trial. On behalf of the campath-1H Study Group. Blood 2002;100:802[abstract].
12. Skotnicki AB, Robak T, Mayer J, Craig A, Weitman S. Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia. Blood 2003;102:439[abstract].
13. Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, et al. Safety and efficacy of subcutaneous campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87:695-700.
14. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jaeger J, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia in first remission. Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-101.
15. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with CLL. Cancer 2003;98:2657-63.
16. - T cells in B-cell chronic lymphocytic leukaemia. Blood 2003;102:1057-63.
17. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, et al. Phase II study of alentuzumab in chronic lymphoproliferative disorders. Cancer 2003;98:773-8.
18. Lundin J, Hagberg H, Repp R, Cavallin-Stahal E, Freden S, Jiuliusson G, et al. A phase II study of alentuzumab in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:4267-72
19. Williams TE, Roach J, Rugg T, Brettman L. Frequency of CMV pneumonia following alemtuzumab treatment in lymphoid malignancies: review of 1538 patients. Blood 2002;100:294.
20. Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. Fatal adenovirus infection during alemtuzumab treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukaemia. Med Oncol 2002;19:277-80.
21. Nabhan C, Tallman MS, Riley MB, Fitzpatrick J, Gordon LI, Gartenhaus R, et al. Phase I study of rituximab and campath-1H in patients with relapsed and refractory chronic lymphocytic malignancies. Blood 2001;98:365[abstract].
22. Faderl S, Tomas D, O'Brirn S, Wierda W, Kantarjian HM, Garcia-Manero G, et al. Combined use of alemtuzumab and rituximab in patients with relapsed/refractory chronic lymphoid malignancies. An update of M. D. Anderson experience. Blood 2003;101:3413-5.
23. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, O'Gorman P, Chakaverti R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63.
24. Bainton RD, Byme JL, Davy B, Russel N. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002;100:3843-4.
25. Juliusson G, Karlsson K, Frodin U, Backstrom G, Malm C. Subcutaneous Campath-1H instead of thymoglobulin in nonmyeloablative allogeneic peripheral blood stem cell transplantation: reduced toxicity but delayed lymphocyte recovery leading to more mixed chimerism, more fatal infections and impaired long-term survival: a single center study of 56 patients. Blood 2002;100 Suppl 1:430[abstract].
26. Kroger N, Thomson K, Zabelina T, Peggs K, Chopra R, Shimoni A, et al. Comparison between anti-thymocyte globulin and alemtuzumab in melphalan/fludarabine dose-reduced conditioning following by HLA-matched and mismatched unrelated stem cell transplantation in patients with lymphoid malignancies. Blood 2003;102:484[abstract].
27. Koh LP, Rizzieri DA, Long GD, Vredemburg JJ, Gasparetto C, Morris A, et al. Campath-1H T cell depleted non-myeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members. Blood 2002;100 Suppl 1:638[abstract].
28. Smith SM, Stock V, Sher D, Wickrema A, Odenike T, Zimmermann T, et al. Engraftment and early-treatment- related complications after fludarabine-melphalan-campath conditioning in patients with advanced hematologic malignancies. Blood 2002;100 Suppl 2:430b[abstract].
29. Cobbold M, Khan N, Tauro S, Mc Donald D, Osman H, Assenmacher M, et al. Adoptive transfer of tetramer selected cytomegalovirus-specific cytotoxic cells after allogeneic stem cell transplantation. Blood 2002;100:215[abstract].
30. Chakrabarti S, Collingham KE, Marshall T, Holder K, Gentle T, Hale G, et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001;72:1460-3.
31. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell depleted marrow transplants in campath users. Blood 1998;91:3079-83.
32. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N, et al. Reconstitution of Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-42.